An evaluation of metabolite profiling of six drugs using dried blood spot

References

• Ahn, C.Y., Bae, S.K., Bae, S.H., Kang, H.E., Kim, S.H., Lee, M.G., and Shin, W.G. (2011). Pharmacokinetics of sildenafil and its metabolite, N-desmethylsildenafil, in rats with liver cirrhosis and diabetes mellitus, alone and in combination. Xenobiotica. 41: 164–174.
   PubMedGoogle Scholar
• Alonen A, Finel M, Kostiainen R. (2008). The human UDP-glucuronosyltransferase UGT1A3 is highly selective towards N2 in the tetrazole ring of losartan, candesartan, and zolarsartan. Biochem Pharmacol 76:763–72.
   PubMed Web of Science ®Google Scholar
• Bowen CL, Volpatti J, Cades J, et al. (2012). Evaluation of glucuronide metabolite stability in dried blood spots. Bioanalysis 4:2823–32.
   PubMed Web of Science ®Google Scholar
• Bu HZ, Zhao P, Dalvie DK, Pool WF. (2007). Identification of primary and sequential bioactivation pathways of carbamazepine in human liver microsomes using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 21:3317–22.
   PubMed Web of Science ®Google Scholar
• Busby MG, Jeffcoat AR, Bloedon LT, et al. (2002). Clinical characteristics and pharmacokinetics of purified soy isoflavones: single-dose administration to healthy men. Am J Clin Nutr 75:126–36.
   PubMed Web of Science ®Google Scholar
• Cassidy KC, Yi P. (2017). Qualitative and quantitative prediction of human in vivo metabolic pathways in a human hepatocyte-murine stromal cell co-culture model. Xenobiotica 16:1–14.
   Google Scholar
• Coldham NG, Zhang AQ, Key P, Sauer MJ. (2002). Absolute bioavailability of [14C] genistein in the rat; plasma pharmacokinetics of parent compound, genistein glucuronide and total radioactivity. Eur J Drug Metab Pharmacokinet 27:249–58.
   PubMed Web of Science ®Google Scholar
• Dalvie D, Zhang C, Chen W, et al. (2010). Cross-species comparison of the metabolism and excretion of zoniporide: contribution of aldehyde oxidase to interspecies differences. Drug Metab Dispos 38:641–5.
   PubMed Web of Science ®Google Scholar
• Ducharme, J. and Farinotti, R. (1996). Clinical Pharmacokinetics and Metabolism of Chloroquine Focus on Recent Advancements. Clin. Pharmacokinet. 31: 257–274.
   PubMedGoogle Scholar
• D'Arienzo CJ, Ji QC, Discenza L, et al. (2010). DBS sampling can be used to stabilize prodrugs in drug discovery rodent studies without the addition of esterase inhibitors. Bioanalysis 2:1415–22.
   PubMed Web of Science ®Google Scholar
• Fischer L, Mahoney C, Jeffcoat AR, et al. (2004). Clinical characteristics and pharmacokinetics of purified soy isoflavones: multiple-dose administration to men with prostate neoplasia. Nutr Cancer 48:160–70.
   PubMed Web of Science ®Google Scholar
• Hosoda K, Furuta T, Yokokawa A, Ishii K. (2010). Identification and quantification of daidzein-7-glucuronide-4'-sulfate, genistein-7- glucuronide-4'-sulfate and genistein-4',7-diglucuronide as major metabolites in human plasma after administration of kinako. Anal Bioanal Chem 397:1563–72.
   PubMed Web of Science ®Google Scholar
• Kehler JR, Bowen CL, Boram S, Evans C. (2010). Application of DBS for quantitative assessment of the peptide Exendin-4; comparison of plasma and DBS method by UHPLC-MS/MS. Bioanalysis 2:1461–8.
   PubMed Web of Science ®Google Scholar
• Kwon SH, Kang MJ, Huh JS, et al. (2007). Comparison of oral bioavailability of genistein and genistin in rats. Int J Pharm 337:148–54.
   PubMed Web of Science ®Google Scholar
• Lertratanangkoon K, Horning MG. (1982). Metabolism of carbamazepine. Drug Metab Dispos 10:110.
   PubMed Web of Science ®Google Scholar
• Li, W., Lee, M. S., (ed.). (2014). Dried blood spots: applications and techniques (Wiley Series on Pharmaceutical Science and Biotechnology: Practices, Applications and Methods), 1st ed. Hoboken, NJ: Wiley, 978–1118.
   Google Scholar
• Mauriala T, Chauret N, Oballa R, et al. (2005). A strategy for identification of drug metabolites from dried blood spots using triple-quadrupole/linear ion trap hybrid mass spectrometry. Rapid Commun Mass Spectrom 19:1984–92.
   PubMed Web of Science ®Google Scholar
• Pearce RE, Vakkalagadda GR, Leeder JS. (2002). Pathways of carbamazepine bioactivation in vitro I. Characterization of human cytochromes P450 responsible for the formation of 2- and 3-hydroxylated metabolites. Drug Metab Dispos 30:1170–9.
   PubMed Web of Science ®Google Scholar
• Pearce RE, Uetrecht JP, Leeder JS. (2005). Pathways of carbamazepine bioactivation in vitro: II. The role of human cytochrome P450 enzymes in the formation of 2-hydroxyiminostilbene. Drug Metab Dispos 33:1819–26.
   PubMed Web of Science ®Google Scholar
• Pearce RE, Lu W, Wang Y, et al. (2008). Pathways of carbamazepine bioactivation in vitro. III. The role of human cytochrome P450 enzymes in the formation of 2,3-dihydroxycarbamazepine. Drug Metab Dispos 36:1637–49.
   PubMed Web of Science ®Google Scholar
• Remmel RP, Sinz MW, Cloyd JC. (1990). Dose-dependent pharmacokinetics of carbamazepine in rats: determination of the formation clearance of carbamazepine-10,11-epoxide. Pharm Res 07:513–7.
   Google Scholar
• Shen Z, Kang P, Rahavendran SV. (2012). Metabolite profiling of dasatinib dosed to Wistar Han rats using automated dried blood spot collection. J Pharm Biomed Anal 67–68:92–7.
   PubMed Web of Science ®Google Scholar
• Sistla A, Yang WL, Shenoy N. (2006). High-performance liquid chromatographic method for determination of reversible isomers of SU5416. J Chromatogr A 1110:73–80.
   PubMed Web of Science ®Google Scholar
• Speed B, Bu HZ, Pool WF, et al. (2012). Pharmacokinetics, distribution, and metabolism of [14C]sunitinib in rats, monkeys, and humans. Drug Metab Dispos 40:539–55.
   PubMed Web of Science ®Google Scholar
• Stearns RA, Miller RR, Doss GA, et al. (1992). The metabolism of DuP 753, a nonpeptide angiotensin II receptor antagonist, by rat, monkey, and human liver slices. Drug Metab Dispos 20:281–7.
   PubMed Web of Science ®Google Scholar
• Stearns RA, Chakravarty PK, Chen R, Chiu SH. (1995). Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members. Drug Metab Dispos 23:207–15.
   PubMed Web of Science ®Google Scholar
• Stove CP, Ingels AS, De Kesel PM, Lambert WE. (2012). Dried blood spots in toxicology: from the cradle to the grave? Crit Rev Toxicol 42:230–43.
   PubMed Web of Science ®Google Scholar
• Suva MA. (2014). A brief review on dried blood spots applications in drug development. J Pharm BioSci 1:17–23.
   Google Scholar
• Titus E.O. (1989). Recent developments in the understanding of the pharmacokinetics and mechanism of action of chloroquine. Ther Drug Monit. 11:369–379.
   PubMedGoogle Scholar
• Wagner M, Tonoli D, Varesio E, Hopfgartner G. (2016). The use of mass spectrometry to analyze dried blood spots. Mass Spectrom Rev 35:361–438.
   PubMed Web of Science ®Google Scholar
• Walker DK, Ackland MJ, James GC, et al. (1999). Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica 29:297–310.
   PubMed Web of Science ®Google Scholar
• Wang L, Zeng Z, Emmons G. (2010). Exploring the feasibility of using the DBS technique for metabolite radioprofiling. Bioanalysis 2:1365–71.
   PubMed Web of Science ®Google Scholar
• Wickremsinhe E. (2015). Dried blood spot analysis for rat and dog studies: validation, hematocrit, toxicokinetics and incurred sample reanalysis. Bioanalysis 7:869–83.
   PubMed Web of Science ®Google Scholar
• Wickremsinhe ER, Callies S, Schmalz CA, et al. (2018). Incorporating dried blood spot LC-MS/MS analysis for clinical development of a novel oncolytic agent. Bioanalysis 10:341–56.
   PubMed Web of Science ®Google Scholar
• Zhang, Z., Zhu M., and Tang, W. (2009). Metabolite Identification and Profiling in Drug Design: Current Practice and Future Directions. Current Pharmaceutical Design, 15, 2220–2235.
   PubMedGoogle Scholar